NCT00715910 - The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults | Biotech Hunter

Enrollment

818

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

October 31, 2013

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Nimenrix

One dose, as intramuscular injection

PROCEDURE

Blood sampling

Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).

Trial Locations (10)

94015

GSK Investigational Site, Daly City

94063

GSK Investigational Site, Redwood City

94533

GSK Investigational Site, Fairfield

94589

GSK Investigational Site, Vallejo

94596

GSK Investigational Site, Walnut Creek

95815

GSK Investigational Site, Sacramento

96792

GSK Investigational Site, Waianae

96797

GSK Investigational Site, Waipio

96814

GSK Investigational Site, Honolulu

96819

GSK Investigational Site, Honolulu